Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intra-Cellular Therapies Inc ITCI

Healthcare
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical... see more

Recent & Breaking News (NDAQ:ITCI)

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

GlobeNewswire 1 day ago

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

GlobeNewswire October 17, 2024

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

GlobeNewswire September 23, 2024

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

GlobeNewswire August 28, 2024

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

GlobeNewswire August 8, 2024

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

GlobeNewswire August 7, 2024

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

GlobeNewswire August 7, 2024

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

GlobeNewswire July 24, 2024

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

GlobeNewswire June 18, 2024

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

GlobeNewswire June 10, 2024

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

GlobeNewswire May 23, 2024

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

GlobeNewswire May 8, 2024

Intra-Cellular Therapies Reports First Quarter 2024 Financial Results

GlobeNewswire May 7, 2024

Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast

GlobeNewswire April 30, 2024

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire April 24, 2024

Intra-Cellular Therapies Prices Public Offering of Common Stock

GlobeNewswire April 17, 2024

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

GlobeNewswire April 16, 2024

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

GlobeNewswire April 16, 2024

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

GlobeNewswire March 19, 2024